ორშაბათი, აპრილი 13, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Botanical

Rose Petals

Rosa

Also known as: Rose petal extract, Rosa sp., Rosehip petals, Rose flower

LOW RISK 1.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 1.0/10).

02

Safety Profile

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Rose petals (Rosa species) are used as a traditional herbal ingredient for antioxidant, anti-inflammatory, and mild astringent effects. They have an excellent safety record as a food and traditional tea ingredient. No significant drug interactions or adverse effects documented at supplemental doses. High tannin content may reduce iron absorption when consumed together.

Classification

Biological and Chemical Classification

Scientific Name
Rosa
Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Botanical
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Botanical
Ingredient Rose Petals
Scientific name Rosa
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Botanical
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • No significant safety signals identified in the reviewed literature.
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Rose Petals indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Rose Petals
Evidence reviewed 10 peer-reviewed studies (last 10 years)
Scientific name Rosa
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 06 აპრ 2026, 12:10

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Effect of Persian traditional medicine based herbal vaginal gel in vaginal atrophy. ↗
    PMID 41930850 ↗
    Journal J Ayurveda Integr Med
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41930850/
    Naderi-Afshar E et al.. Effect of Persian traditional medicine based herbal vaginal gel in vaginal atrophy.. J Ayurveda Integr Med. 2026. PMID:41930850.
  2. Observational / other LOW evidence YELLOW
    Fermentation quality and microbial communities of mixed silage from Pennisetum glaucum u00d7 purpureum and Rosa roxburghii residue. ↗
    PMID 41922943 ↗
    Journal BMC Microbiol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41922943/
    Kaiyue P et al.. Fermentation quality and microbial communities of mixed silage from Pennisetum glaucum u00d7 purpureum and Rosa roxburghii residue.. BMC Microbiol. 2026. PMID:41922943.
  3. Observational / other LOW evidence YELLOW
    Evaluation of the Hypoglycemic Mechanism of a Polyherbal Formulation by Integrating Network Pharmacology and Pharmacology Experiments. ↗
    PMID 41918409 ↗
    Journal Chem Biodivers
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41918409/
    Liu L et al.. Evaluation of the Hypoglycemic Mechanism of a Polyherbal Formulation by Integrating Network Pharmacology and Pharmacology Experiments.. Chem Biodivers. 2026. PMID:41918409.
  4. Observational / other LOW evidence YELLOW
    Molecular basis of drought tolerance in Rosa xanthina: an integrated analysis of physiology, transcriptome, and NAC transcription factor. ↗
    PMID 41917830 ↗
    Journal BMC Genomics
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41917830/
    Li Z et al.. Molecular basis of drought tolerance in Rosa xanthina: an integrated analysis of physiology, transcriptome, and NAC transcription factor.. BMC Genomics. 2026. PMID:41917830.
  5. Observational / other LOW evidence YELLOW
    Machine learning integrates metabolomics and proteomics to identify key regulators of anthocyanin biosynthesis in edible rose petals. ↗
    PMID 41907760 ↗
    Journal Front Plant Sci
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41907760/
    Fu D et al.. Machine learning integrates metabolomics and proteomics to identify key regulators of anthocyanin biosynthesis in edible rose petals.. Front Plant Sci. 2026. PMID:41907760.
  6. Observational / other LOW evidence YELLOW
    Ethnobotanical study of wild edible plants in Dabat District, Ethiopia. ↗
    PMID 41906185 ↗
    Journal Trop Med Health
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41906185/
    Kegne T et al.. Ethnobotanical study of wild edible plants in Dabat District, Ethiopia.. Trop Med Health. 2026. PMID:41906185.
  7. Observational / other LOW evidence YELLOW
    Risk Factors of Residual Obstructive Sleep Apnea After Adenotonsillectomy in Children: Systematic Review. ↗
    PMID 41901520 ↗
    Journal Medicina (Kaunas)
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41901520/
    Stockunaite P et al.. Risk Factors of Residual Obstructive Sleep Apnea After Adenotonsillectomy in Children: Systematic Review.. Medicina (Kaunas). 2026. PMID:41901520.
  8. Observational / other LOW evidence YELLOW
    Cili (Rosa roxburghii Tratt.) as a Functional Food and Medicinal Resource: Current Advances and Future Directions. ↗
    PMID 41899401 ↗
    Journal Curr Issues Mol Biol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41899401/
    Zhang J et al.. Cili (Rosa roxburghii Tratt.) as a Functional Food and Medicinal Resource: Current Advances and Future Directions.. Curr Issues Mol Biol. 2026. PMID:41899401.
  9. Observational / other LOW evidence YELLOW
    Genome-Wide Bioinformatics Identification and Functional Analysis of the 3-ketoacyl-CoA Synthase (KCS) Gene Family in Rosa u00d7 hybrida, with Focus on RcKCS6. ↗
    PMID 41898820 ↗
    Journal Genes (Basel)
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41898820/
    Peng Y et al.. Genome-Wide Bioinformatics Identification and Functional Analysis of the 3-ketoacyl-CoA Synthase (KCS) Gene Family in Rosa u00d7 hybrida, with Focus on RcKCS6.. Genes (Basel). 2026. PMID:41898820.
  10. Observational / other LOW evidence YELLOW
    Mechanistic Insights into Active Components of Rosa Roxburghii Juice Against Fluoride-Induced Osteoarthritis. ↗
    PMID 41897456 ↗
    Journal Antioxidants (Basel)
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41897456/
    Du Y et al.. Mechanistic Insights into Active Components of Rosa Roxburghii Juice Against Fluoride-Induced Osteoarthritis.. Antioxidants (Basel). 2026. PMID:41897456.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 1.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 1.0 / 10

Final GIRI Score for Rose Petals. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 1.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
1.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Rose Petals

GIRI Score 1.0 / 10

A score of 1.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

ბოლო სიახლეები

პოპულარული ამბები

კატეგორიები

ჩვენ შესახებ

info@accreditation.ge
ჩვენს შესახებ / რეკლამა / კონტაქტი

გამოგვყევი სოციალურ ქსელებში

© SheniEkimi.ge